EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study

Atsuyuki Igarashi iD, Toshio Katsunuma iD, Takayo Matsumura iD, Hiroshi Komazaki iD, Nemolizumab-JP04 Study Group

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad268 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Atsuyuki Igarashi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maruho Co. Ltd, Chugai Pharmaceutical Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is a chronic, inflammatory skin condition affecting up to one-quarter of children. Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep and development. The humanized monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus and improve QoL in patients with AD aged ≥ 13 years. However, data relating to its efficacy and safety in younger children (aged < 13 years) have been lacking.

Objectives

To evaluate the efficacy and safety of nemolizumab, administered concomitantly with topical agents, in Japanese paediatric patients (aged 6–12 years) with AD and inadequately controlled moderate-to-severe pruritus.

Methods

This was a randomized, placebo-controlled, double-blind, parallel-group, multicentre, 16-week, phase III study. Patients aged ≥ 6 and < 13 years, with confirmed AD, and an inadequate pruritic response despite treatment with topical agents and oral antihistamines were randomly assigned (1 : 1) to receive nemolizumab 30 mg or placebo every 4 weeks (Q4W). The primary efficacy endpoint was the change in the weekly mean 5-level itch score from baseline to week 16; secondary efficacy endpoints were related to pruritus, indicators for AD and QoL. Safety was assessed via adverse events (AEs) and laboratory test results.

Results

In total, 89 patients were enrolled, received either nemolizumab 30 mg (n = 45) or placebo (n = 44) Q4W, and completed the study. The mean patient age was 9.1 (SD 1.9) years, and mean duration of AD was 8.5 (2.7) years. The change in 5-level itch score from baseline to week 16 showed a statistically significant difference in the nemolizumab treatment group (−1.3) compared with placebo (−0.5; least-squares mean difference −0.8, 95% confidence interval −1.1 to −0.5; P < 0.0001). Improvements with nemolizumab were observed from the second day of administration. Secondary endpoints were in favour of nemolizumab. No AEs resulted in discontinuation, and the overall safety profile in patients aged 6–12 years was comparable with that in older patients (aged ≥ 13 years) with AD.

Conclusions

Nemolizumab is a potential new treatment option for paediatric patients with AD whose pruritus has not been sufficiently improved with topical treatments and antihistamines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansChildAgedQuality of LifeInjections, SubcutaneousPruritusHistamine AntagonistsDouble-Blind MethodTreatment OutcomeSeverity of Illness IndexAntibodies, Monoclonal, Humanized

Substanzen

Histamine AntagonistsnemolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan.
  • Department of Pediatrics, Daisan Hospital, The Jikei University School of Medicine, Tokyo, Japan.
  • Clinical Development Department, Maruho Co. Ltd, Kyoto, Japan.

ORCID-Profile: Atsuyuki Igarashi, Toshio Katsunuma, Takayo Matsumura, Hiroshi Komazaki

Förderung

  • Maruho Co. Ltd
  • Chugai Pharmaceutical Co. Ltd

Zitieren

APA

Igarashi, A., Katsunuma, T., Matsumura, T., Komazaki, H., & Nemolizumab-JP04 Study Group (2023). Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad268

Vancouver

Igarashi A, Katsunuma T, Matsumura T, Komazaki H, Nemolizumab-JP04 Study Group. Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad268

BibTeX
@article{Igarashi2023,
  author = {Igarashi, Atsuyuki and Katsunuma, Toshio and Matsumura, Takayo and Komazaki, Hiroshi and Nemolizumab-JP04 Study Group, Nemolizumab-JP04 Study Group},
  title = {Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad268}
}
Kostenlos starten →